Drug Trial Radar · NCT03737214
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Dec 18, 2018
Primary completion
Aug 31, 2026
Study completion Oct 6, 2026
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. This study includes a sub-study evaluating kidney Gb3 inclusions (and other histologic lesions) in male participants with classic Fabry disease who have been treated for at least 2 years with lucerastat monotherapy in study ID-069A302.
Conditions
- Fabry Disease
Interventions
LucerastatDrug
Administered in hard gelatin capsules containing 250 mg of lucerastat.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (AEs)Time frame: From enrollment to Follow-up 1 (FU1) visit; duration: for up to 10 years including 1 month Follow-up
Locations
42 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Nephrology Research Clinic
Birmingham, Alabama
University of California Irvine
Irvine, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
University of Florida Clinical and Translational Science Institute, UF Clinical Research Center
Gainesville, Florida
Rush University Medical Center - Dept of Pediatrics
Chicago, Illinois
University of Iowa Stead Family Children's Hospital - Division of Medical Genetics
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Infusion Associates
Grand Rapids, Michigan
University of Pennsylvania - Dept of Medicine
Philadelphia, Pennsylvania
Greenwood Genetics Center
Greenville, South Carolina
Renal Disease Research Institute LLC
Dallas, Texas
Baylore University Medical Center
Dallas, Texas
University of Utah - Division of Medical Genetics, Clinical Genetics Research
Salt Lake City, Utah
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fairfax, Virginia
Royal Melbourne Hospital - Department of Nephrology
Parkville, Australia
Royal Perth Hospital, Department of Nephrology
Perth, Australia
Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse
Vienna, Austria
University Hospital Ghent (UZ Ghent)
Ghent, Belgium
University Hospital Gasthuisberg, Leuven (UZ Leuven)
Leuven, Belgium
University of Calgary - Heritage Medical Research Clinic
Calgary, Canada
London Health Sciences CTR, Victoria Hospital
London, Canada
Research Center, Hôpital du Sacré-Coeur de Montréal
Montreal, Canada
Vancouver General Hospital - Adult Metabolic Diseases Clinic
Vancouver, Canada
Children's Hospital Research Institute of Manitoba
Winnipeg, Canada
Raymond Poincaré Hosp - Med Genetics Dept
Garches, France
Universitätsmedizin Berlin - Charité Campus Mitte
Berlin, Germany
SphinCS GmbH
Höchheim, Germany
Nephrologicum Markgräflerland MVZ GmbH
Müllheim, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Hospital Academisch Medisch Centrum - Department of Internal Medicine, Div. Endrocrinology and Metabolism
Amsterdam, Netherlands
Haukeland University Hospital
Bergen, Norway
Clinic of Immunological Diseases and Blood Coagulability Cracow University Hospital
Krakow, Poland
Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego - Państwowy Instytut Badawczy
Warsaw, Poland
The Children's Memorial Health Institute, Department of Pediatric, Nutrition and Metabolic Diseases
Warsaw, Poland
Vall d'Hebron University Hospital - Unit of Inherited Metabolic Disorders and Rare Diseases
Barcelona, Spain
Hospital Universitari de Bellvitge / Nephrology Dpt
Barcelona, Spain
Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna
Madrid, Spain
Hospital Quironsalud Zaragoza
Zaragoza, Spain
Psychiatrische Universitätsklinik Zürich
Zurich, Switzerland
Royal Free London NHS Foundation Trust Lysosomal Storage Disorder Unit; Department of Hematology
London, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.